MedPath

Real-world Research : Assessment of Effect of Combination of Drugs in the Treatment of Heart Failure

Not yet recruiting
Conditions
Heart Failure
Registration Number
NCT06158711
Lead Sponsor
Qianfoshan Hospital
Brief Summary

The goal of this observational study is to assess the effect of the different combination of drugs in the treatment of heart failure.

The main questions it aims to answer are:

* \[question 1\] The changes of BNP and LVEF in patients of each groups with different drugs co-administration.

* \[question 2\] The days of hospitalization, degree of lower limb edema (mild, moderate, severe) and 6-minute walking test in each groups.

Participants will be asked to do nothing. All the records of the patients will be download from the Big Data Cloud Platform of Health Care in the First Affiliated Hospital of Shandong First Medical University.

There is not a comparison group.

Detailed Description

The purpose of this study is to evaluate the efficacy and cost-effective of different drugs co-administration in the treatment of heart failure. For different reasons, patients with heart failure took different drug prescriptions. Now there are five kinds of drugs for the treatment of heart failure, such as angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB), beta-blokers, spironolactone, sodium-glucose cotransporter (sglt) 2 inhibitors and vericiguat. Our purpose is to assessment the efficacy and cost-effective of different drugs co-administration in the treatment of heart failure.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
702
Inclusion Criteria
  • Patients diagnosed as "heart failure" or "cardiac insufficiency" on the first page of the medical record
Exclusion Criteria
  • Severe impairment of liver, kidney and lung function (transaminase increased more than 2 times; Scr > 265umol/L); malignant tumor

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The B-type natriuretic peptide (BNP)Admission to hospital and 12 months thereafter

B-type natriuretic peptide (BNP) is a marker of heart failure. Its levels can be measured with a rapid and commercially available bed-side assay. Rising levels correlate with the degree of left ventricular dysfunction and severity of symptoms.

Left ventricular ejection fraction (LVEF) of patientsAdmission to hospital and 12 months thereafter

Echocardiography is the gold standard for establishing the presence of left ventricular dysfunction. Left ventricular ejection fraction (LVEF) is the central measure of left ventricular systolic function. LVEF is the fraction of chamber volume ejected in systole (stroke volume) in relation to the volume of the blood in the ventricle at the end of diastole (end-diastolic volume).

Hospital mortalityIndex hospital stay

We recorded the death from heart failure, no matter the mode of death.

Secondary Outcome Measures
NameTimeMethod
Days of hospitalization and expenses of patientsIndex hospital stay

The hospitalization days and expenses of patients admitted with different drugs treatment were examined.

6-minute walking testAdmission to hospital and 12 months thereafter

The 6-minute walking test (6MWT) is a widely available and well-tolerated test for the assessment of the functional capacity of patients with HF.

degree of lower limb edema (mild, moderate, severe)Admission to hospital and 12 months thereafter

Lower-extremity edema is one of the important factors in diagnosing, monitoring, and managing HF status. A senior cardiologist checked carefully for the presence of bilateral lower-extremity edema and graded its severity on a scale of 1 of 4 based on the extent of the edema in the leg, as follows: (1) none, (2) up to the height of the ankle level (mild edema), (3) up to the height of the knee (moderate edema), and (4) higher than knee level (severe edema).

© Copyright 2025. All Rights Reserved by MedPath